The role of plasminogen activator inhibitor-2 in pneumococcal meningitis

Nina C. Teske1,2,3, Joo-Yeon Engelen-Lee2,3, Susanne Dyckhoff-Shen1, Hans-Walter Pfister1, Matthias Klein1,3, Diederik van de Beek2,3, Carsten K. Kirschning4, Uwe Koedel1,3† and Matthijs C. Brouwer2,3*†

Abstract

Pneumococcal meningitis is associated with dysregulation of the coagulation cascade. Previously, we detected upregulation of cerebral plasminogen activator inhibitor-2 (PAI-2) mRNA expression during pneumococcal meningitis. Diverse functions have been ascribed to PAI-2, but its role remains unclear. We analyzed the function of SERPINB2 (coding for PAI-2) in patients with bacterial meningitis, in a well-established pneumococcal meningitis mouse model, using Serpinb2 knockout mice, and in vitro in wt and PAI-2-deficient bone marrow-derived macrophages (BMDMs).

We measured PAI-2 in cerebrospinal fluid of patients, and performed functional, histopathological, protein and mRNA expression analyses in vivo and in vitro. We found a substantial increase of PAI-2 concentration in CSF of patients with pneumococcal meningitis, and up-regulation and increased release of PAI-2 in mice. PAI-2 deficiency was associated with increased mortality in murine pneumococcal meningitis and cerebral hemorrhages. Serpinb2−/− mice exhibited increased C5a levels, but decreased IL-10 levels in the brain during pneumococcal infection. Our in vitro experiments confirmed increased expression and release of PAI-2 by wt BMDM and decreased IL-10 liberation by PAI-2-deficient BMDM upon pneumococcal challenge. Our data show that PAI-2 is elevated during pneumococcal meningitis in humans and mice. PAI-2 deficiency causes an inflammatory imbalance, resulting in increased brain pathology and mortality.

Keywords: Pneumococcal meningitis, Plasminogen activator inhibitor-2, SERPINB2

Introduction

Pneumococcal meningitis (PM) is the most common form of bacterial meningitis and is associated with high mortality and risk of neurological sequelae [5, 6]. Cerebrovascular complications are an important cause of poor outcome and death [34, 38]. Activation of the coagulation cascade and inhibition of fibrinolysis have been shown to be associated with the risk of cerebral infarction in meningitis [7, 33, 43, 44]. A direct interaction by pneumococcal virulence factors with coagulation or fibrinolysis factors has been suggested, although it is difficult to dissect whether this is independent of the inflammatory response [41].

Plasminogen activator inhibitor-1 (PAI-1) is an important regulator of fibrinolysis by inhibiting tissue plasminogen activator (tPA) and urokinase (uPA) mediated proteolytic degradation of fibrin clots [23]. In a study on the role of PAI-1 in PM we showed that the functional genetic variation rs1799889 in SERPINE1 (coding for PAI-1) influenced the risk of cerebral infarction, hemorrhage, poor disease outcome and mortality in patients [7]. Subsequently, in a mouse model of PM we demonstrated that PAI-1-deficiency resulted in higher mortality and increased cerebral hemorrhages, suggesting a protective role of PAI-1 [7].

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Analogous to PAI-1, PAI-2 (also known as SERPINB2) is classically viewed as an inhibitor of extracellular uPA and tPA, even if PAI-2 is slower than PAI-1 at inhibiting these proteases (in vitro) [10, 15]. However, it is unclear what its key function is, given that the vast majority of PAI-2 is located intracellularly in the cytoplasm. A broad range of activities has been ascribed to PAI-2, such as regulation of monocyte proliferation and differentiation [46], priming interferon α/β responses [3], inhibition of annexin-1 cleavage [13], interleukin 1β processing [17] and also apoptosis [14]. Despite over 1000 publications on PAI-2, no consensus view on its (patho)physiological function has been reached, which has led to labels like “the undecided Serpin” [29].

Some studies using PAI-2-deficient mice showed that PAI-2 can modulate Th1/Th2 immune response, implicating a role in adaptive immunity [27, 36, 37, 47]. Our knowledge of the PAI-2 functions in innate immunity is limited. PAI-2 antigen could be detected in the plasma of sepsis patients and was associated with mortality [21, 35]. In PAI-2-deficient mice however, no differences to wild type (wt) mice in survival were found after challenge with endotoxin or cecal ligation and puncture [11]. An in vitro model of mononuclear cells showed stimulation with B. burgdorferi induced production and secretion of PAI-2. This resulted in significantly diminished uPA-dependent invasion by mononuclear cells, proposing a role of PAI-2 in leukocyte migration [20]. Studies focusing on the regulation of PAI-2 expression after stimulation with bacteria and/or bacterial components showed significant up-regulation of PAI-2 expression in mononuclear cell and/or macrophages upon exposure [4, 20, 39, 40]. In a mouse model of PM, we observed a strong upregulation of PAI-2 mRNA expression in brains of infected mice [33]. So, it seems apparent that PAI-2 is formed during bacterial infections, but the specific role PAI-2 plays in infections remains unclear.

To determine the role of PAI-2 during PM we analyzed PAI-2 concentrations in cerebrospinal fluid of pneumococcal meningitis patients and immunohistochemically stained PAI-2 in brains of patients who died of pneumococcal meningitis. Subsequently, we compared the disease course in wt versus PAI-2-deficient mice and the response of wt versus PAI-2-deficient BMDM upon pneumococcal challenge.

Methods

Dutch bacterial meningitis cohort
In a nationwide prospective cohort study, we included patients with community-acquired bacterial meningitis with an age of 16 years or older with positive CSF cultures who were identified by The Netherlands Reference Laboratory for Bacterial Meningitis (NRLBM) from March 2006 to October 2011 [5, 25]. The NRLBM provided the names of the hospitals where patients with bacterial meningitis had been admitted 2–6 days previously. The treating physician was contacted, and written informed consent was obtained from all participating patients or their legally authorized representatives, and controls. Methods of the study have been described in detail previously [5]. The study was approved by the Medical Ethics Committee of the Academic Medical Center, Amsterdam, The Netherlands.

CSF PAI-2 analysis
CSF of patients with PM (n = 268) was obtained from the diagnostic lumbar puncture and subsequently stored at − 80°C. Control CSF samples (n = 14) were obtained from patients with benign thunderclap headache in whom a lumbar puncture was performed to rule out subarachnoid hemorrhage. CSF PAI-2 levels were determined using the Millipore Luminex kit according to the manufacturer’s instructions (Merck Millipore, MA, USA). We performed association analysis between the CSF concentrations of PAI-2 on admission and the clinical outcome (as measured by the Glasgow outcome scale, GOS) as well as the occurrence of cerebrovascular complications (comprising cerebral infarction and hemorrhages) in patients with pneumococcal meningitis. An unfavourable outcome was defined as a GOS score of 1–4, and a favorable outcome was defined as a score of 5. Cerebrovascular infarction and hemorrhages were defined as focal neurologic signs on admission or during the course of the disease with consistent findings on cranial computed tomography or magnetic resonance imaging.

PAI-2 expression of human meningitis cases
Brain sections were obtained from patients included in the Dutch bacterial meningitis cohort. The brains were macroscopically examined, followed by formalin fixation. The sampled cut-up blocks were then embedded in paraffin, cut and stored. Brain sections were stained with primary antibodies directed against PAI-2 (Bio-Connect, Netherlands, dilution 1:100), the respective secondary antibody and chromogen. After counterstaining with haematoxylin solution, tissue sections were examined using a Carl Zeiss Axioskop light microscope.

Animal pneumococcal meningitis model
We used a well-characterized mouse model of PM [22]. Briefly, mice were weighed, scored clinically, and the temperature was taken. Clinical scoring comprised a beam walk test, a postural reflex test, presence/absence of pilo-erection, reduced vigilance, and/or seizures. The maximum clinical score was 13, indicating moribund
mice that had to be euthanized due to ethical considerations, whereas a score of 0 defined uninfected healthy mice. After initial clinical evaluation, bacterial meningitis was induced by intracisternal injection of 15 µl of 10^7 colony forming units (cfu) per ml Streptococcus pneumoniae type 2 (D39 strain, kindly provided by Prof. Sven Hammerschmidt, University of Greifswald, Germany) under short-term anesthesia with isoflurane. To assess the role of PAI-2 in the development of meningitis, infected mice were observed for 24 h. To get insight into PAI-2 function in more advanced disease, mice were treated with ceftriaxone at 24 h to prevent death from overwhelming infection and assessed at 48 h post infection. At the end of each experiment, animals were clinically examined again. Thereafter, mice were anaesthetized with ketamine/xylazine, and a catheter was placed into the cisterna magna to obtain cerebrospinal fluid (CSF) samples for white blood cell (WBC) counts. Subsequently, animals were perfused transcardially with ice cold phosphate buffered saline (PBS). The cerebellum was dissected and homogenized in 1 ml sterile PBS for determination of bacterial titers. Cerebellar homogenates were diluted serially, plated on blood agar plates, and cultured for 24 h before colony forming units (CFU) were counted. Intracerebral hemorrhages were determined in frozen mouse brains, which were cut in a frontal plane into 10 µm thick sections. From the anterior parts of the lateral ventricles, ten serial sections were photographed with a digital camera at 0.3 mm intervals throughout the ventricle system. Hemorrhagic spots were counted, and – in selected experiments—the bleeding area was measured.

Measurement of cytokine expression
In mice surviving up to the 48-h time-point, concentrations of C5a, IL-10, and IL-1β in homogenized brains were determined by ELISA (R&D Systems, Germany), according to the manufacturers’ instructions. Cytokine concentrations were given as amount of cytokine per mg brain protein.

Experimental groups in the mouse model
The following experimental groups were investigated: (1) male C57BL6 wt mice injected intracisternally with 15 µl of PBS (so-called controls; n = 4 investigated 24 h after infection and n = 6 investigated 48 h after infection, respectively); (2) wt mice injected intracisternally with 15 µl of S. pneumoniae (n = 9 investigated 24 h after infection and n = 8 investigated 48 h after infection, respectively); (3) Serpinb2-deficient mice injected intracisternally with 15 µl S. pneumoniae (Serpinb2^-/-), backcrossed for more than 10 generations onto the C57BL6 background, n = 9 investigated 24 h after infection and n = 12 investigated 48 h after infection, respectively. Supplemental experimental groups were carried out to analyze PAI-2 protein concentrations in murine CSF and plasma over the course of the disease, namely uninfected controls (n = 5), infected wt mice investigated 24 and 48 h after infection, respectively (n = 12 in each group).

Immunohistochemical analysis
Brains from control and meningitic wt and Serpinb2-deficient mice were fixed in 10% formalin, embedded in paraffin, and cut into 7 µm sections. Brain sections were stained with primary antibodies directed against PAI-2 (ab137588, Abcam, dilution 1:100) and MRP-14, a marker for neutrophils (Invitrogen Antibodies, dilution 1:2000), the respective secondary antibodies and chromogens. After counterstaining with hematoxylin solution, tissue sections were examined using an Olympus BX-51 light microscope and images captured with a cooled Moticam 5000 video camera connected to a PC.

Cell culture experiments with BMDM
Bone marrow–derived macrophages (BMDMs) were prepared from bone marrow cells obtained from femurs as described previously [22]. PAI-2-deficient and wt BMDM were exposed to increasing concentrations of the serotype 2 pneumococcal strain D39 (up to 10^6 cfu/ml; that corresponds to MOI=10). Four h after infection, BMDM were treated with ceftriaxone (100 µg/ml). Again 20 h later, medium samples were withdrawn and analyzed for cell viability using a commercially available LDH assay (Enzo Life Sciences) and for the presence of IL-10, IL-6, IL-1β (using ELISA kits from R&D Systems), and PAI-2 (using an ELISA Kit from FineTest®). We also isolated RNA from both infected and control PAI-2-deficient and wt BMDM and assessed the expression of the macrophage surface markers CX3CR1, ITGAM (CD11b), MRC1 (CD206), and CD36, of the macrophage phenotype markers iNOS and ARG1, as well as of PAI-2 by RT-PCR (using commercially available PrimePCR™ primer pairs from Biorad).

Statistical analysis
Statistical tests were performed using GraphPad Prism and SPSS software. The principal statistical test was a Mann–Whitney U test for continuous variables, for grouped analyses a two-way ANOVA with Tukey’s multiple comparisons test or a log-rank test (Mantel) for survival. For correlation analysis we used spearman’s rank correlation coefficient. Differences were considered significant at P<0.05. Patient data are displayed as median±interquartile ranges (IQR), mouse data as mean±standard deviation.
Study approval
The animal experiments were approved by the animal ethic committee of the government of Upper Bavaria, Germany (AZ 211–2531-67/99 und -47/08).

Results
PAI-2 is released into the CSF and blood during pneumococcal meningitis
We measured PAI-2 levels in CSF samples from 268 patients with PM. The median level of PAI-2 was 387 ng/ml (Interquartile range [IQR] 197—618), which was higher than CSF PAI-2 concentrations in 14 controls (median 18 ng/ml; IQR 0.3—27; \( p < 0.001 \)) (Fig. 1a). CSF PAI-2 concentrations on admission were significantly higher in patients with an unfavourable outcome of pneumococcal meningitis (median 520 ng/ml, IQR 336–796 vs. 297 ng/ml, IQR 175–471 in patients with a favorable outcome; \( p < 0.001 \)). CSF PAI-2 levels were also higher in patients who suffered cerebrovascular complications compared to those who did not (median 487 ng/ml IQR 331–749 vs. 370 ng/ml, IQR 193–542, \( p = 0.02 \)).

CSF PAI-2 was significantly correlated to CSF protein concentration (\( r = 0.63, p < 0.001 \)). Immunohistochemical investigations showed strong PAI-2 staining in the inflammatory infiltrate in the leptomeningeal space (Fig. 1b, c).

Subsequently, we investigated whether the findings in patients with PM correspond to those in the mouse model. Previously, we observed a 15-fold up-regulation in PAI-2 mRNA expression in the brain of meningitis mice 24 h after pneumococcal infection compared to uninfected control mice [33]. Consistent with this, we found a marked increase in PAI-2 protein levels in CSF and plasma samples collected at 24 h after pneumococcal inoculation (median 285 ng/ml CSF PAI-2; IQR 192 – 419 versus median 8 ng/ml CSF PAI-2; IQR 3–19; \( p < 0.0001 \)) (Fig. 1d, e). At 48 h CSF PAI-2 levels were not significantly different. Comparable to the patient data, the immunohistochemical examination showed PAI-2 positive cells particularly in the leukocyte infiltrate in the leptomeningeal space (Fig. 1f, g) and the ventricular system.

Taken together, we found a substantial up-regulation and release of PAI-2 in patients and mice with PM.

PAI-2 deficiency is associated with worse outcome of murine pneumococcal meningitis
To get better insight into the functional role of PAI-2 in PM, we compared the disease phenotype of PAI-2-deficient mice (\( \text{Serpinb2}^{-/-} \)) to that of wt mice. In a first series of experiments, mice were examined 24 h after intracisternal inoculation of \( \text{S. pneumoniae} \). At this time point, \( \text{Serpinb2}^{-/-} \)-mice showed signs of the disease that were identical to those of wt mice. There were no differences between groups in the numbers of CSF leukocytes and cerebral hemorrhages as well as...
in pneumococcal titers in the brain and blood. Consequently, PAI-2 does not seem to play a critical role in the initial stages of meningitis. Different results emerged when PAI-2-deficient mice were evaluated at advanced stages of the disease, 48 h after infection. In these experiments, mice were treated with ceftriaxone after 24 h comparable to a clinical situation. PAI-2 deficiency did not affect pneumococcal killing by ceftriaxone, CSF pleocytosis and clinical score values of surviving mice. Five of 12 PAI-2-deficient mice (41%) died before the end of the experiment, compared to none of the wt mice (Log-rank $P = 0.04$; Fig. 2a).

Upon opening of the skull intracerebral ($n = 1$), subarachnoidal ($n = 3$) and subdural hemorrhages ($n = 1$) were detectable in 4 of 12 $\text{Serpinb2}^{−/−}$ mice (33%) compared to none of the wt mice (Fig. 2b–e). Pathological brain examination revealed a greater number of hemorrhagic spots and larger total bleeding areas in PAI-2-deficient mice as compared to wt mice (mean number of hemorrhagic spots 63.6 $\text{Serpinb2}^{−/−}$ vs. 25.4 wt, $p < 0.001$; mean total bleeding area 5.53 mm$^2$ $\text{Serpinb2}^{−/−}$ vs. 1.15 mm$^2$ wt, $p < 0.001$; Fig. 2f, g). The increase in cerebral hemorrhages was accompanied with a more pronounced immune reactivity against MRP-14, a known marker of neutrophils, in infected $\text{Serpinb2}^{−/−}$ mice compared to infected wt mice (Fig. 3). Thus, a higher level of neutrophilic infiltration around parenchymal vessels may contribute to the increase in cerebral hemorrhages in PAI-2-deficient mice with PM.

$\text{Serpinb2}^{−/−}$ mice exhibited increased C5a levels, but decreased IL-10 levels in the brain during pneumococcal infection

PAI-2 was previously reported to suppress IL-1β production by controlling caspase-1 activation [9, 17]. In addition, PAI-2 deficiency can lead to increased uPA/tPA-dependent plasmin activity, which is capable of converting C5 into its active form C5a, thus resulting in elevated C5a concentrations [2, 12]. Both, IL-1β and C5a are known mediators of hyper-inflammation and vascular damage in murine PM [42]. This motivated us to determine C5a and IL-1β concentrations in brains of infected wt and PAI-2-deficient mice and also measure brain levels of IL-10, a key anti-inflammatory cytokine in PM [24, 45, 48]. $\text{Serpinb2}^{−/−}$ with PM had higher C5a concentrations (Fig. 4a), but lower IL-10 levels (Fig. 4b). Brain IL-1β levels were similar in both mouse strains (Fig. 4c). These data suggest dysregulated inflammation as a possible contributing factor of the aggravated brain pathology of PAI-2-deficient mice.

PAI-2 deficiency led to decreased IL-10 release by BMDM upon pneumococcal infection

Since macrophages express high levels of PAI-2 upon Toll-like receptor (TLR) activation [9, 17] and regulate innate immune responses to bacterial infections, we next examined the expression of PAI-2 and its functional relevance in murine BMDM upon pneumococcal challenge. Quantitative RT-PCR analysis showed a marked
up-regulation of PAI-2 mRNA expression in wt BMDM, which was absent in PAI-2-deficient cells (Fig. 5a). A concentration-dependent release of PAI-2 was observed by wt BMDM into the cell culture supernatant (Fig. 5b). This liberation started at a non-cytolytic concentration of $10^5$ cfu/ml (MOI = 1) $S. pneumoniae$ and increased sharply with the onset of macrophage lysis. The comparative RT-PCR analysis of selected macrophage surface and activation markers such as CD11b (ITGAM), CD206, iNOS or ARG did not reveal any differences in their expression levels between BMDM obtained from wt and PAI-2-deficient mice. There were also no differences between both genotypes in the release of the pro-inflammatory cytokines IL-1β and IL-6. However, PAI-2-deficient BMDM responded to $S. pneumoniae$ challenge by a significantly decreased IL-10 liberation compared to wt BMDM (Fig. 5c). Taken together, our in vitro experiments showed a selective influence of PAI-2 deficiency on pneumococcal-induced IL-10 expression by BMDM, which is consistent with our observation in the mouse model.

**Discussion**

Our results show PAI-2 expression in the inflammatory infiltrate and PAI-2 liberation into the CSF in patients and mice with PM. In mice with PM, PAI-2 deficiency was associated with increased mortality. The higher mortality was accompanied by an increase in number and size of intracerebral hemorrhages, possibly due to aggravated neutrophilic inflammation, especially around parenchymal vessels. Increased neutrophilic infiltration was paralleled by increased C5a and reduced IL-10 concentrations.
in brains of infected PAI-2-deficient mice, pointing to an immunoregulatory function of PAI-2 in PM. Consistent with this, murine BMDM showed increased PAI-2 production as well as reduced IL-10 release in the absence of PAI-2 after pneumococcal challenge.

PAI-2 is one of the major molecules up-regulated in monocytes and macrophages upon TLR2 and/or TLR4 engagement [9]. Accordingly, increased PAI2 expression and/or release was found in cell cultures of these cells following exposure to *Borrelia burgdorferi*, *Pseudomonas aeruginosa*, *Helicobacter pylori*, bacterial DNA, and meningococcal LPS-containing outer membrane vesicles [4, 20, 39, 40]. As we demonstrated in this study, infection with *S. pneumoniae* also leads to increased expression of PAI-2 and its massive release both in vitro and in vivo (animal model and patients). These observations point to a function of PAI-2 in the regulation of innate immunity. There are only a few publications in patients with sepsis [32, 35] that have addressed this hypothesis, even though mice deficient in PAI-2 have been available as a suitable tool for investigating this question for over 20 years [11]. In the initial publication, the authors showed that *Serpinb2*−/− mice exhibited normal development, survival, and fertility. *Serpinb2*−/− mice were found to exhibit no differences to wt mice in monocyte recruitment into the peritoneum after thioglycolate injection, in the degree of arterial and venous thrombosis after LPS injection into the footpad, and in survival after challenge with LPS or cecal ligation and puncture. In contrast to this negative initial phenotype analysis, it has since been reported that PAI-2-deficient mice differ from normal mice in their disease phenotype in schistosomal, lentiviral, and enteric nematode infections due to an altered TH1/TH2 immunity [27, 36, 47]. In mouse models of acute neurodegeneration, it has been shown that deficiency of PAI-2 limits brain oedema development following traumatic brain injury but did not influence lesion volume after cerebral trauma or infarction [18, 19].

In our mouse PM model, we now observed a distinct disease phenotype: PAI-2 deficiency was associated with increased mortality, which was paralleled by a substantial increase in intracerebral hemorrhages. This disease phenotype is similar to the phenotype we previously found in PAI-1-deficient (*Serpine1*−/−) mice [7]. Like PAI-1, PAI-2 is considered to be an authentic and physiological inhibitor of uPA and tPA within extracellular environments [1, 30]. Consequently, a lack of PAI-2 could lead to an increased formation of plasmin from plasminogen and thus to an imbalance between the coagulation and fibrinolysis system with an increased risk of bleeding. This is supported by our observations that PAI-2 deficiency was associated with increased cerebral
hemorrhages in experimental PM. However, the histopathological examinations of murine brains demonstrated a substantial difference between Serpinb2−/− and Serpine1−/− mice. In Serpinb2−/− mice, the increase in cerebral hemorrhages was associated with pronounced neutrophilic infiltrates, while in Serpine1−/− mice the increase in bleeding was not accompanied by enhanced inflammation around parenchymal vessels. In Serpine1−/− mice, cerebral hemorrhage occurred also in the absence of perivascular infiltrates. This finding suggests mechanistic differences between both genotypes. In contrast to the PAI-1, PAI-2 appears to be involved in the regulation of inflammation. This is supported by our observation that Serpinb2−/− mice had higher brain C5a levels, but lower brain IL-10 concentrations than wt mice 24 h after the start of antibiotic therapy. Previous work by our and other groups has demonstrated that C5a is a critical driver of inflammation in PM, while IL-10 appears to be an important antagonist [24, 45]. The altered expression of C5a and IL10 is likely to result in an immune imbalance in favor of a continued pro-inflammatory state. However, to what extent increased inflammation and increased fibrinolysis due to PAI2 deficiency contribute to development of cerebral hemorrhages is unclear.

How PAI-2 affects C5a and IL-10 concentrations is unclear. In myeloid cells, IL-10 production is induced by various signals downstream of pattern-recognition receptors alongside that of pro-inflammatory cytokines such as IL-1β [28, 31]. Large amounts of IL-1β are produced and released during PM [16]. Genetic and pharmacological interference with IL-1β generation leads to a milder immune response (and a better outcome) [22]. Recently,
PAI-2 expression in macrophages has been shown to suppress IL-1β production, presumably via increasing autophagy and NLRP3 degradation, resulting in decreased caspase-1 activation [28, 31]. In our in vivo and in vitro experiments, however, PAI-2 deficiency had no impact on IL-1β production. Thus, the lower IL-10 production in the absence of PAI-2 does not appear to be related to lower IL-1β production. Consequently, the IL-10 reduction appears to be based on an IL-1beta independent mechanism that has yet to be elucidated.

The conversion of plasminogen to plasmin is tightly controlled by the availability of plasminogen activators and their inhibitors such as PAI-2. Plasmin is the only enzyme that is able to cleave complement C5 at a similar rate as the canonical C5 convertase [26], generating biological active C5a [2, 12]. Accordingly, PAI-2 deficiency could lead to increased plasmin activity and thus, to increased C5a production in PM. This pathway can contribute to a prolonged pro-inflammatory state, causing enhanced perivascular inflammation, increased cerebral hemorrhages, and reduced survival.

The analysis of CSF PAI-2 levels in patients indicating high levels of PAI-2 are associated with poor outcome are contrasting with the mouse experiments showing absence of PAI-2 causes worse outcome. Several explanations for this discrepancy can be provided: first, timing of CSF sampling was variable in patients, who were in different stages of the disease with variable duration and severity of symptoms, different underlying conditions, virulence of bacteria etc. Second, PAI-2 CSF levels were correlated to CSF protein levels, which indicates at least part of the PAI-2 came from leakage through the blood–brain-barrier. Finally, PAI-2 may play a role at different stages of the disease, which is difficult to extrapolate from the single measurement in CSF. Our mouse experiments show that PAI-2 deficiency is associated with increased cerebral hemorrhages, an aggravated immune response, and consequently an unfavourable clinical course. This fits well with the biological activities known so far for PAI-2.

We show Serpinb2−/− mice have a clear disease phenotype in PM that is associated with increased perivascular neutrophilic infiltration and heavier bleeding. These observations fit with the previously discussed concepts of an immunoregulatory role of PAI-2 in pathophysiological conditions. Our study has several limitations. First, although we were able to connect the pathological changes with changes in the brain concentrations of C5a and IL-10 we were unable to clarify the underlying mechanism of these changes. Furthermore, in the animal experiments only animals surviving the full 48 h were assessed for clinical scores, weight loss, temperature, exploratory behavior, CSF white blood cell count, bacterial cerebellar titer, and brain protein cytokine concentrations. As deceased mice can be assumed to be more severely affected on most (or all) of these parameters, relevant clinical features of meningitis in PAI-2-mice may have been missed as numbers were too small to show statistically significant differences. Finally, we did not quantify fibrinolysis by measuring uPA, tPA and plasmin activity due to no (or a limited amount of) left-over CSF, blood and brain tissue. We did not feel that additional mouse experiments for this purpose only were justified.

**Conclusion**

In conclusion, our data suggests that PAI-2 has an anti-inflammatory role in pneumococcal meningitis. PAI-2 deficiency increased C5a and reduced IL-10 concentration, resulting in increased mortality due to brain hemorrhages. SerpinB2 has been studied as a potential treatment in a mouse stroke model and proven to be effective in reducing brain damage [8]. Therefore, a similar therapeutic approach may be tested in a mouse PM model to assess its efficacy against meningitis-associated vascular damage and death.

**Abbreviations**

BMDM: Bone marrow-derived macrophages; CFU: Colony forming units; CSF: Cerebrospinal fluid; IQR: Interquartile ranges; PAI-1: Plasminogen activator inhibitor-1; PAI-2: Plasminogen activator inhibitor-2; PBS: Phosphate buffered saline; PM: Pneumococcal meningitis; THY: Todd Hewitt Broth with yeast; TLR: Toll-like receptor; WBC: White blood cell.

**Acknowledgements**

We thank Barbara Angele for technical support, and all Dutch physicians participating in the MeninGene study. MCB is supported by a grant from the Netherlands Organization for Health Research and Development (ZonMw; NWO-Vidi Grant 2017 [917.17.308] and the European Research Council (ERC Consolidator Grant 2021 [101001237]). DvdB is supported by grants from the Netherlands Organization for Health Research and Development (ZonMw; ZonMw; NWO-Vici grant 2019 [918.186.27] to DvdB). UK is supported by grants from the German research foundation (UK1974/9-1 und UK1974/10-1).

**Author contributions**

NCT performed the analyses and drafted the manuscript; JEL and SDS performed experiments and provided comments on the manuscript; HWP, MK, CH and DvdB participated in its design and coordination and provided comments on the manuscript. UK and MCB designed and performed the experiments and provided comments on the manuscript. All authors read and approved the final manuscript.

**Funding**

This study has been funded by grants from the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Research Grant 2011 to MCB), European Federation of Neurological Sciences (EFNS Scientific Fellowship 2011 to MCB), Netherlands Organization for Health Research and Development (ZonMw; NWO-Veni grant 2012 [916.13.078] to MCB). The study was performed as collaborative project of the European Society for Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Infections of the Brain (ESGIB).

**Availability of data and materials**

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
Declarations

Ethics approval and consent to participate
The clinical study was approved by the Medical Ethics Committee of the Academic Medical Center, Amsterdam, The Netherlands. Written informed consent was obtained from all participating patients, or their legally authorized representatives, and controls. The animal experiments were approved by the animal ethics committee of the government of Upper Bavaria, Germany (AZ 211–2531-67/99 und -47/08).

Consent for Publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Laboratory of Neuroinfectious Diseases, Department of Neurology, Klinikum Großhadern, Ludwig-Maximilians University, Munich, Germany. 2 Department of Neurology, Amsterdam UMC, University of Amsterdam, Amsterdam Neuroscience, PO Box 22660, 1100 DD Amsterdam, The Netherlands. 3 European Society for Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Infections of the Brain (ESGIB), Basel, Switzerland. 4 Institute of Medical Microbiology, University of Duisburg-Essen, Essen, Germany.

Received: 7 September 2022  Accepted: 12 October 2022  Published online: 29 October 2022

References

1. Al-Horani R (2014) Serpin regulation of fibrinolytic system: implications for therapeutic applications in cardiovascular diseases. Cardiovasc Hematol Agents Med Chem 12:91–125. https://doi.org/10.2174/187152571266614106095927
2. Amara U, Flierl M, Rittirsch D, Klos A, Chen H, Acker B et al (2010) Molecular intercommunication between the complement and coagulation systems. J Immunol 185:5628–5636. https://doi.org/10.4049/jimmunol.0903678
3. Antalis T, La Linn M, Donnan K, Mateo L, Gardner J, Dickinson J et al (1998) Plasminogen activator inhibitor type 2 protects against viral cytopathic effects by constitutive interferon alpha/beta priming. J Exp Med 187:1799–1811. https://doi.org/10.1084/jem.187.11.1799
4. Berk R, Katar M, Dong Z, Day D (2001) Plasminogen activators and inhibitors in the corneas of mice infected with pseudomonas aeruginosa. Invest Ophthalmol Vis Sci 42:1561–1567
5. Biljsma M, Brouwer M, Kasanmoentahil E, Koeck A, Lucas M, Tanck M et al (2016) Community-acquired bacterial meningitis in adults in the Netherlands, 2006–14: a prospective cohort study. Lancet Infect Dis 16:339–347. https://doi.org/10.1016/S1473-3099(16)30430-2
6. Brouwer M, Heckenberg S, De Gans J, Spanjaard L, Reitsma J, Van De Beek D (2010) Nationwide implementation of adjunctive dexamethasone for therapeutic applications in cardiovascular diseases. Cardiovasc Hematol Agents Med Chem 12:1703–1705. https://doi.org/10.2174/1871525710012104
7. Brouwer M, Meijers J, Baas F, Van Der Erde A, Pfister H, Giese A et al (2014) Plasminogen activator inhibitor-1 influences cerebrovascular complications and death in pneumococcal meningitis. Neurology 75:1530–1539. https://doi.org/10.1212/25wb.0000000000000297
8. Brouwer M, Meijers J, Baas F, Van Der Erde A, Pfister H, Giese A et al (2014) Plasminogen activator inhibitor-1 influences cerebrovascular complications and death in pneumococcal meningitis. Acta Neuropathol 127:533–564. https://doi.org/10.1007/s00401-013-1216-4
9. Buchthal B, Weiss U, Bading H (2018) Post-injury nose-to-brain delivery of activin a and serpinb2 reduces brain damage in a mouse stroke model. Mol Ther 26:2357–2365. https://doi.org/10.1016/j.ymthe.2018.07.018
10. Croucher D, Saunders D, Lobov S, Ranson M (2008) Revisiting the biological roles of paiz2 (serpinb2) in cancer. Nat Rev Cancer 8:535–545. https://doi.org/10.1038/Ncancer2400
11. Dougherty K, Pearson J, Yang A, Westrick R, Baker M, Ginsburg D (1999) The plasminogen activator inhibitor-2 gene is not required for normal murine development or survival. Proc Natl Acad Sci U S A 96:6868–691. https://doi.org/10.1073/pnas.96.2.6868
12. Fowler J, Walton B, Alemann M, Obyme A, Levi V, Harrasser M et al (2016) Complement activation in arterial and venous thrombosis is mediated by plasmin. EBioMedicine 5:175–182. https://doi.org/10.1016/j.ebiom.2016.02.011
13. Gan H, Lee J, Ren F, Chen M, Kornfeld H, Remold H (2008) Mycobacterium tuberculosis blocks crosslinking of annexin-1 and apoptotic envelope formation on infected macrophages to maintain virulence. Nat Immunol 9:1189–1197. https://doi.org/10.1038/Ni.1654
14. Gan H, Newman G, Remold H (1995) Plasminogen activator inhibitor type 2 prevents programmed cell death of human macrophages infected with mycobacterium avium, serovar 4. J Immunol 155:1304–1315
15. Gardner E, Medcalf R (2014) Is plasminogen activator inhibitor type 2 really a plasminogen activator inhibitor after all? J Thromb Haemost 12:1703–1705. https://doi.org/10.1111/jth.12704
16. Grandirard D, Gaumann R, Coulibaly B, Dangy J, Sie A, Junghanss T et al (2013) The causative pathogen determines the inflammatory profile in cerebrospinal fluid and outcome in patients with bacterial meningitis. Mediators Inflamm. https://doi.org/10.1155/2013/121476
17. Greten F, Arkan M, Bollethia J, Hsu L, Goede J, Wethingt C et al (2002) NF-kappab is a negative regulator of IL-1beta secretion as revealed by genetic and pharmacological inhibition of ikkbeta. Cell 130:918–931. https://doi.org/10.1016/j.cell.2007.07.009
18. Griemert E, Hedrich J, Hirtel T, Thal S (2019) Deficiency of plasminogen activator inhibitor type 2 limits brain edema formation after traumatic brain injury. J Neurotrauma 36:2272–2278. https://doi.org/10.1089/neu.2018.6126
19. Griemert E, Recarte-Pelz K, Engelhard K, Schafer M, Thal S (2019) Pai-1 but not pai-2 gene deficiency attenuates ischemic brain injury after experimental stroke. Transl Stroke Res 10:372–380. https://doi.org/10.1007/s12975-018-0644-9
20. Haile W, Coleman J, Benach J (2006) Reciprocal upregulation of urokinase plasminogen activator and its inhibitor, pai-2, by borella burgdorferi affects bacterial penetration and host-inflammatory response. Cell Microbiol 8:1349–1360. https://doi.org/10.1111/j.1462-5822.2006.00717.x
21. Haj M, Robbie L, Adley G, Bennett B (1995) Inhibitors of plasminogen activator in neutrophils and mononuclear cells from septic patients. Thromb Haemost 74:1528–1532
22. Hoegen T, Tremel N, Klein M, Angele B, Wagner H, Kirschning C et al (2011) The Nfibrp3 inflammasome contributes to brain injury in pneumoccal meningitis and is activated through atp-dependent lysosomal cathepsin B release. J Immunol 187:5440–5451. https://doi.org/10.4049/jimmunol.1100790
23. Iwaki T, Urano T, Umemura K (2012) Pae-1, progress in understanding the clinical problem and its aetiology. Br J Haematol 157:291–298. https://doi.org/10.1111/j.1365-2457.2012.09704.x
24. Koedel U, Bernatowicz A, Frei K, Fontana A, Pfister H (1996) Systemically (but not intrathecally) administered il-10 attenuates pathophysiologic alterations in experimental pneumococcal meningitis. J Immunol 157:5185–5191
25. Lee S, Fiverbera B, Kremer P, Wheele N, Sereon M, Croucher N et al (2019) Joint sequencing of human and pathogen genomes reveals the genetics of pneumococcal meningitis. Nat Commun 10:2176. https://doi.org/10.1038/s41467-019-09976-3
26. Leung L, Moser J (2016) Plasmin as a complement C5 convertase. EBioMedicine 5:20–21. https://doi.org/10.1016/j.ebiom.2016.03.015
27. Major L, Partridge T, Gardner J, Kent S, De Rose R, Suhrbier A et al (2013) The causative pathogen determines the inflammatory profile in cerebrospinal fluid and outcome in patients with bacterial meningitis. Mediators Inflamm. https://doi.org/10.1155/2013/312476
28. Manzanillo F, Edenschenk C, Ouyang W (2015) Deciphering the crosstalk among Il-1 and Il-10 family cytokines in intestinal immunity. Trends Immunol 36:471–478. https://doi.org/10.1016/j.it.2015.06.003
29. Medcalf R, Stasinopoulos S (2005) The undecorated serpin. The ins and outs of plasminogen activator inhibitor type 2. F ebs J 272:4858–4867. https://doi.org/10.1038/nj.2005.879X
30. Mukhopadhyay S, Ta J, Sarkar R, Tri A (2018) Serpins in venous thrombosis and venous thrombus resolution. Methods Mol Biol 1826:197–211. https://doi.org/10.1007/978-1-4939-8645-3_13
31. Ouyang W, Ogura A (2019) II-10 family cytokines II-10 and II-22: from basic science to clinical translation. Immunobiology 224:871–891. https://doi.org/10.1016/J.immuni.2019.03.020
32. Paramo J, Perez J, Serrano M, Rocha E (1990) Types 1 and 2 plasminogen activator inhibitor and tumor necrosis factor alpha in patients with sepsis. Thromb Haemost 64:3–6
33. Paul R, Winkler F, Bayerleim I, Popp B, Hw P, Koedel U (2005) Urokinase-type plasminogen activator receptor regulates leukocyte recruitment during experimental pneumococcal meningitis. J Infect Dis 191:776–782. https://doi.org/10.1086/427829
34. Pfister H, Borasio G, Dinnagl U, Bauer M, Einhaupl K (1992) Cerebrovascular complications of bacterial meningitis in adults. Neurology 42:1497–1504
35. Robbie I, Dummer S, Booth N, Asey G, Bennett B (2000) Plasminogen activator inhibitor 2 and urokinase-type plasminogen activator in plasma and leukocytes in patients with severe sepsis. Br J Haematol 109:342–348. https://doi.org/10.1046/j.1365-2141.2000.02057.x
36. Schroder W, Gardner J, Le T, Duke M, Burke M, Jones M et al (2010) Serpinb2 deficiency modulates Th1/Th2 responses after schistosome infection. Parasite Immunol 32:764–788. https://doi.org/10.1111/j.1365-3034.2010.01241.x
37. Schroder W, Major L, Suhrbier A (2011) The role of serpinb2 in immunity. Crit Rev Immunol 31:15–30
38. Schut E, Lucas M, Brouwer M, Vernou M, Van Der Ende A, Van De Beek D (2012) Cerebral infarction in adults with bacterial meningitis. Neurocrit Care 16:421–427. https://doi.org/10.1007/S12028-011-9634-4
39. Semeraro N, Montemurro P, Piccoli C, Muolo V, Colucci M, Giuliani G et al (1996) Effect of helicobacter pylori lipopolysaccharide (LPS) on the production of tissue factor and plasminogen activator inhibitor type 2 by human blood mononuclear cells. J Infect Dis 174:1255–1260. https://doi.org/10.1093/Infdis/174.6.1255
40. Kj S, MJ S, Da H (1996) Macrophages ingest and are activated by bacterial DNA. J Immunol 157:2116–2122
41. Takemura M, Yamaguchi M, Kobayashi M, Sumitomo T, Hirose Y, Okuzaki D et al (2007) Pneumococcal bgaa promotes host organ bleeding and coagulation in a mouse sepsis model. Front Cell Infect Microbiol 12:844000. https://doi.org/10.3389/Fcimb.2022.844000
42. Van De Beek D, Brouwer M, Koedel U, Wall E (2021) Community-acquired bacterial meningitis. Lancet 398:1171–1183. https://doi.org/10.1016/S0140-6736(21)00883-7
43. Winkler F, Kastenbauer S, Koedel U, Pfister H (2002) Role of the urokinase plasminogen activator system in patients with bacterial meningitis. Neurology 59:1350–1355. https://doi.org/https://doi.org/10.1212/01.WNL.0000031427.81988.96
44. Woehrl B, Brouwer M, Murr C, Heckenberg S, Baas F, Pfister H et al (2011) Complement component 5 contributes to poor disease outcome in humans and mice with pneumococcal meningitis. J Clin Invest 121:3943–3953. https://doi.org/10.1172/Jci67522
45. Yu H, Maurer F, Ri M (2002) Plasminogen activator inhibitor type 2: a regulator of monocyte proliferation and differentiation. Blood 99:2810–2818. https://doi.org/10.1182/Blood.V99.8.2810
46. Zhao A, Yang Z, Sun R, Grinchuk V, Netzeli Ametti S, Anglin I et al (2013) Serpinb2 is critical to Th2 immunity against enteric nematode infection. J Immunol 190:5779–5787. https://doi.org/10.4049/jimmunol.1200293
47. Zwijnenburg P, Van Der Poll T, Florquin S, Roord J, Van Furth A (2003) Interleukin-10 negatively regulates local cytokine and chemokine production but does not influence antibacterial host defense during murine pneumococcal meningitis. Infect Immun 71:2276–2279. https://doi.org/10.1128/iai.71.4.2276-2279.2003

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.